Merrimack Pharmaceuticals (MACK) News Today → Make this ONE trade on Tuesday at 2 p.m. EST! (From Monument Traders Alliance) (Ad) Free MACK Stock Alerts $15.13 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 10:25 AM | investorplace.comMACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q1 2024May 16 at 9:56 AM | marketbeat.comMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Increases Dividend to $15.10 Per ShareMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced a dividend on Thursday, May 16th. Investors of record on Tuesday, May 21st will be paid a dividend of 15.10 per share by the biopharmaceutical company on Friday, May 17th. This represents a yield of 99.87%. The ex-dividend date of this dividend is Monday, May 20th. This is a positive change from Merrimack Pharmaceuticals's previous dividend of $1.50.May 15 at 1:44 AM | americanbankingnews.comMerrimack Pharmaceuticals (NASDAQ:MACK) Cut to "Sell" at StockNews.comMay 10, 2024 | marketwatch.comMerrimack Pharmaceuticals Shareholders OK Dissolution PlanMay 10, 2024 | businesswire.comMerrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common StockMay 10, 2024 | americanbankingnews.comMerrimack Pharmaceuticals (NASDAQ:MACK) Shares Pass Above Two Hundred Day Moving Average of $13.75May 9, 2024 | msn.comMerrimack Pharmaceuticals intends to declare $15.10 dividendMay 9, 2024 | finance.yahoo.comMerrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of DissolutionApril 30, 2024 | businesswire.comMerrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of DissolutionApril 20, 2024 | seekingalpha.comMACK Merrimack Pharmaceuticals, Inc.April 3, 2024 | finance.yahoo.comDiagonal starts up with $128M to make better ‘activator’ antibody drugsMarch 27, 2024 | businesswire.comMerrimack Receives $225 Million Milestone Payment from IpsenMarch 26, 2024 | marketbeat.comMerrimack Pharmaceuticals (NASDAQ:MACK) Shares Cross Above 200 Day Moving Average of $13.19Merrimack Pharmaceuticals (NASDAQ:MACK) Stock Crosses Above Two Hundred Day Moving Average of $13.19March 18, 2024 | marketbeat.comMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Sees Large Drop in Short InterestMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK - Get Free Report) was the recipient of a large drop in short interest in February. As of February 29th, there was short interest totalling 774,100 shares, a drop of 5.9% from the February 14th total of 822,900 shares. Based on an average daily volume of 92,100 shares, the days-to-cover ratio is presently 8.4 days.March 8, 2024 | msn.comStocks Gain as U.S. Unemployment Report Bolsters the Outlook for Fed Rate CutsMarch 8, 2024 | investorplace.comMACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023March 7, 2024 | businesswire.comMerrimack Reports Full Year 2023 Financial ResultsMarch 5, 2024 | marketbeat.comMerrimack Pharmaceuticals (NASDAQ:MACK) Shares Cross Above Two Hundred Day Moving Average of $12.93Merrimack Pharmaceuticals (NASDAQ:MACK) Stock Price Crosses Above 200 Day Moving Average of $12.93March 4, 2024 | finance.yahoo.comMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of the companyFebruary 22, 2024 | benzinga.comMerrimack Pharmaceuticals Stock (NASDAQ:MACK), Analyst Ratings, Price Targets, PredictionsFebruary 17, 2024 | finance.yahoo.comMACK Mar 2024 14.000 putFebruary 17, 2024 | finance.yahoo.comMACK Mar 2024 4.000 putFebruary 15, 2024 | markets.businessinsider.comOnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical OfficerFebruary 14, 2024 | finance.yahoo.comMACK Feb 2024 16.000 putFebruary 14, 2024 | finance.yahoo.comIpsen drug approved by FDA for early pancreatic cancerFebruary 13, 2024 | msn.comThe S&P 500, Dow, Nasdaq are down as traders push back forecasts for interest rate cutsFebruary 13, 2024 | marketwatch.comMerrimack Pharmaceuticals to Hold Meeting on Corporate DissolutionFebruary 13, 2024 | finance.yahoo.comMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)February 13, 2024 | businesswire.comMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)February 13, 2024 | marketbeat.comMerrimack Pharmaceuticals (NASDAQ:MACK) Stock Price Passes Above 200 Day Moving Average of $12.65Merrimack Pharmaceuticals (NASDAQ:MACK) Shares Cross Above Two Hundred Day Moving Average of $12.65January 31, 2024 | marketbeat.comMerrimack Pharmaceuticals (NASDAQ:MACK) Stock Price Passes Above 200 Day Moving Average of $12.55Merrimack Pharmaceuticals (NASDAQ:MACK) Shares Cross Above Two Hundred Day Moving Average of $12.55January 31, 2024 | marketbeat.comMerrimack Pharmaceuticals (NASDAQ:MACK) Upgraded at StockNews.comStockNews.com raised shares of Merrimack Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday.January 23, 2024 | marketbeat.comMerrimack Pharmaceuticals (NASDAQ:MACK) Downgraded by StockNews.comStockNews.com downgraded shares of Merrimack Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday.December 28, 2023 | marketbeat.comMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Director Eric Andersen Purchases 857 SharesMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK - Get Free Report) Director Eric Andersen acquired 857 shares of the stock in a transaction dated Thursday, December 28th. The shares were bought at an average price of $13.35 per share, with a total value of $11,440.95. Following the completion of the transaction, the director now directly owns 534,008 shares of the company's stock, valued at $7,129,006.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.December 27, 2023 | marketbeat.comMerrimack Pharmaceuticals (NASDAQ:MACK) Upgraded to Hold at StockNews.comStockNews.com raised shares of Merrimack Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday.December 12, 2023 | msn.com$2M Bet On Ford? Check Out These 4 Stocks Insiders Are BuyingDecember 10, 2023 | finance.yahoo.comWe're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To GrowNovember 10, 2023 | morningstar.comMerrimack Pharmaceuticals Inc MACKNovember 2, 2023 | finance.yahoo.comMerrimack Reports Third Quarter 2023 Financial ResultsOctober 24, 2023 | stockhouse.comOnconova Expands Leadership Team with Two Key AppointmentsOctober 20, 2023 | theglobeandmail.comThe Fight Against Pancreatic Cancer Just Gained a New Ally with $200M VC FirmAugust 15, 2023 | finance.yahoo.comWestern Standard LLC Boosts Stake in Merrimack Pharmaceuticals IncAugust 13, 2023 | insidermonkey.comOnconova Therapeutics, Inc. (NASDAQ:ONTX) Q2 2023 Earnings Call TranscriptAugust 3, 2023 | finance.yahoo.comMerrimack Reports Second Quarter 2023 Financial ResultsJuly 18, 2023 | finanznachrichten.dePharming Group N.V.: Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the BoardJuly 18, 2023 | finance.yahoo.comPharming to nominate industry leader Dr. Richard Peters as new Chairman of the BoardJuly 7, 2023 | marketbeat.comMerrimack Pharmaceuticals (NASDAQ:MACK) Stock Rating Lowered by StockNews.comStockNews.com downgraded Merrimack Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday.June 23, 2023 | marketbeat.comMerrimack Pharmaceuticals (NASDAQ:MACK) Downgraded to "Sell" at StockNews.comStockNews.com cut Merrimack Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday.May 26, 2023 | marketbeat.comMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is 22Nw LP's 6th Largest Position22Nw LP lowered its holdings in shares of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK - Get Rating) by 17.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,015,048 shares of the biopharmaceutical company's stock after selMay 2, 2023 | marketbeat.comShort Interest in Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Increases By 6.7%Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK - Get Rating) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 904,700 shares, a growth of 6.7% from the March 31st total of 847,700 shares. Based on an average daily volume of 91,700 shares, the days-to-cover ratio is currently 9.9 days. Approximately 6.9% of the company's stock are short sold. Get Merrimack Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter. Email Address Make this ONE trade on Tuesday at 2 p.m. EST! (Ad)Every time the U.S. Government releases jobs, inflation, GDP and other Economic Reports… Use The JOLTS Loophole to target up to 253%... 327%... Even 383% Overnight Profits! Discover The Secret Loophole BEFORE Tuesday! MACK Media Mentions By Week MACK Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MACK News Sentiment▼0.950.52▲Average Medical News Sentiment MACK News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MACK Articles This Week▼61▲MACK Articles Average Week Get Merrimack Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: RIGL News EBS News XOMA News VSTM News RGLS News VNDA News LXRX News GTHX News RENB News ATOS News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MACK) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceThe Presidential candidate you should REALLY be worried aboutStansberry ResearchProtect Your Bank Account Before It’s Too LateWeiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressWhat’s Really Next for America…Porter & CompanyHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merrimack Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
